and 33.3%; p ¼ 0.9). 23.4% of patients received second line treatment. The two most commonly used regimens were FOLFIRI (36.4%) and Capecitabine (27.3%). FOLFIRI seemed to be more effective than Capecitabine (respectively 66.7% of progression vs 100%, p ¼ 0.5). Only 4.3% of patients received a third line chemotherapy based on capecitabine or FOLFIRI. All patients progressed. The median number of received chemotherapy cycles was 4. 41.9% of our patients developed grade 3-4 toxicity during chemotherapy. There was no treatment-related death. Median overall survival (OS) and progression free survival (PFS) were respectively 6 and 5 months. On univariate analysis, factors associated with poor OS were elevated tumor markers (p ¼ 0.001), hepatic metastases (p ¼ 0.003) and radiologic progression after first line treatment (p ¼ 0.03). Those related with a better survival were receiving first (p<0.001) and second line chemotherapy (p ¼ 0.01) and having a surgery (p ¼ 0.01) even with a palliative intent (p ¼ 0.04). Multivariate analysis demonstrated that the only independent factor positively impacting on survival was receiving chemotherapy (p ¼ 0.01). Conclusion: Metastatic spread of gastric cancer is fatal. This study confirms the survival benefit and manageable toxicity of palliative chemotherapy but survival increase remains poor compared to improvements in other gastrointestinal cancers.

No abstract

No abstract

fluoropyrimidines, platinum agents, and taxanes. Among them, one patient achieved confirmed partial response, and five pts showed stable disease. The most common treatment-related adverse events (!20% of pts) were rash (60%), anemia (30%), neutropenia (30%), thrombocytopenia (20%), and decreased appetite (20%). The second stage is ongoing. Conclusion: TAS-114 with S-1 showed a preliminary efficacy signal with acceptable safety profiles for heavily pretreated pts with AGC, which would be further confirmed in the ongoing study. P À 071 Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network lysis for the literature of past 20 years

Introduction: There are two different etiologies of gastric cardia cancer -Barrett's esophagus and Helicobacter pylori (H. pylori) associated atrophy/intestinal metaplasia. We aimed to evaluate the clinical characteristics and outcome between gastric cardia and non-cardia cancer. Also, we evaluated the clinical outcome according to obesity, H. pylori infection, and gastric atrophy. Methods: We performed a retrospective cohort study of 90 patients with gastric cardia cancer from Jan. 2003 to 2013. The control group was randomly selected in a 2:1 ratio compared with the case group, and 180 patients with gastric non-cardia cancer were selected as age and sex matched control during the same period. Results: The rate of curative resection (R0), disease free survival and overall survival duration were significantly lower in gastric cardia cancer. The rate of recurrence was significantly higher in gastric cardia cancer (28.4% vs 8.0%, P < 0.01). The rate of H. pylori (-) and gastric atrophy (-) of gastric cardia cancer was statistically higher than non-cardia cancer (P < 0.01), but there was no difference in the rate of obesity. Irrespective of obesity or the presence of H. pylori/gastric atrophy, there were no differences of overall survival, recurrence rate and disease-free survival. Conclusion: Gastric cardia cancer had a negative prognostic impact, compared with gastric non-cardia cancer. Although a possible heterogeneity in the pathogenesis and biological behavior of gastric cardia cancer would be present, there was no difference in prognosis.